Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 1671 - National Mammography Quality Assurance Advisory Committee - Statutory (Congress Created)


Committee NameNational Mammography Quality Assurance Advisory CommitteeAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number1671
Original Establishment Date7/6/1993Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*15
Current Charter Date7/7/2021Designated Fed Officer Position Title*Lead Public Health Analyst, Center for Devices and Radiological Health/FDA
Date Of Renewal Charter7/7/2023Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*James
Exempt From Renewal*NoDesignated Federal Officer Middle NameP
Specific Termination AuthorityDesignated Federal Officer Last Name*Swink
Establishment Authority*Statutory (Congress Created)Designated Federal Officer Suffix
Specific Establishment Authority*42 U.S.C. 263b(n)Designated Federal Officer Phone*(301) 796-6313
Effective Date Of Authority*7/6/1991Designated Federal Officer Fax*(301) 847-8505
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Scientific Technical Program Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The National Mammography Quality Assurance Advisory Committee (NMQAAC) provides advice to the Agency on the following tasks: (1) developing appropriate quality standards and regulations for mammography facilities, (2) developing appropriate standards and regulation for bodies accrediting mammography facilities, (3) developing regulations on sanctions, (4) developing procedures to monitor compliance with standards, (5) establishing a mechanism to investigate consumer complaints, (6) reporting new developments concerning breast imaging that should be considered in the oversight of mammography facilities, (7) determining whether there is a shortage of mammography facilities in rural and health professional shortage areas, (8) determining whether there will be a sufficient number of medical physicists after 1999, and (9) determining the costs and benefits of compliance with these requirements.
How is membership balanced?*The Mammography Quality Standards Act of 1992 (MQSA) specifies that advisory committee members be selected from physicians, practitioners and other health professionals whose clinical practice, research specialization, or professional expertise includes a significant focus on mammography. The Act also directs the appointment of four individuals from among national breast cancer consumer health organizations with expertise in mammography and at least two practicing physicians who provide mammography services. The current committee is composed of M.D.'s and Ph.D's who have expertise in the fields of medical physics, teleradiology, medical physicist, digital mammography, and diagnostic radiology. Consumer interests are represented by mammographers, radiologic technologists and health education specialists.
How frequent & relevant are cmte mtgs?*This committee is mandated by the Mammography Quality Standards Act of 1992 (MQSA) to provide input in the promulgation of reasonable policies to execute the Act. Meetings are to be held annually. No meeting held in FY 22. One meeting is planned for FY 2023.
Why advice can't be obtained elsewhere?*Committee members have backgrounds in academia, research, and/or clinical practice. Their advice and input lends credibility to regulation decisions made and assists those decisions to stand up to intense public scrutiny. The alternate means of accessing this advice would involve the recruitment of large numbers of scientists on a full-time basis at maximum rates of compensation.
Why close or partially close meetings?N/A
Recommendation RemarksAlthough this committee did not meet in FY 2022, considerable time was devoted to reappointing current members, maintaining associated records for these activities, and streamlining paper processes within FDA. In addition, time was spent in the routine care and maintenance of the committee: the development of a financial report for this website; updating the roster and number of vacancies on our website; completing the annual ethics report; reviewing financial disclosures of current members and providing ethics training. Since the Committee did not meet, no reporting was required. This year the Agency plans to publish a request for nominations in the Federal Register Notice, to receive nominations to fill the current and upcoming vacancies.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesYesAction Issued New RegulationsYes
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentIssued new or modified guidance.
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe utilization of the National Mammography Quality Assurance Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis . The service of the Committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.Grants Review CommentNA
Number Of Recommendations*87Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe committee made 87 recommendations from FY03 through FY22.Access Agency WebsiteYes
% of Recs Fully Implemented*84.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*Most of the committee’s recommendations deal with guidance. When the guidance has been finalized, the committee is sent copies of the guidance and the guidance is published as part of the public record. When appropriate, information is made available to the public. Actions related to guidance documents or other general matters or issues are available publicly when implemented. Please see Description*FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The National Mammography Quality Assurance Advisory Committee (NMQAAC) supports FDA's strategic priorities by advising the Food and Drug Administration on the following items, thereby helping FDA meet Objective 3 of Empowering Consumers by improving and increasing FDA-initiated health benefit/risk information:(A)developing appropriate quality standards and regulations for mammography facilities; (B)developing appropriate standards and regulations for bodies accrediting mammography facilities under this program; (C)developing regulations with respect to sanctions;(D)developing procedures for monitoring compliance with standards;(E)establishing a mechanism to investigate consumer complaints;(F)reporting new developments concerning breast imaging which should be considered in the oversight of mammography facilities;(G)determining whether there exists a shortage of mammography facilities in rural and health professional shortage areas and determining the effects of personnel on access to the services of such facilities in such areas; (H)determining whether there will exist a sufficient number of medical physicists after October 1, 1999; and (I)determining the costs and benefits of compliance with these requirements.
Hide Section - COSTS


Payments to Non-Federal Members*$0.00Est Payments to Non-Fed Members Next FY*$589.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$48,262.00Estimated Payments to Federal Staff*$49,578.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$0.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$12,065.00Est. Other Costs Next FY*$12,395.00
Total Costs$60,327.00Est. Total Next FY*$62,562.00
Date Cost Last Modified10/4/2022 8:08 PMEst. Fed Staff Support Next FY*0.25
Federal Staff Support (FTE)*0.25Est Cost Remarks
Cost Remarks  
Hide Section - Interest Areas

Interest Areas

Applied Science
Applied Sciences
Management Science
Patents and Trademarks
Broadcasting and Communications
Computer Technology
Information Technology
Federal Employment
Federal Employees and Personnel
Public Services
Food and Drugs
Food and Drugs
Medical Devices
Health Care
Medical Education
Physical Fitness
International Organizations
Health and Health Research


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-040473National Mammography Quality Assurance Advisory Committee2021
 COM-038748National Mammography Quality Assurance Advisory Committee2020
 COM-036631National Mammography Quality Assurance Advisory Committee2019
 COM-034844National Mammography Quality Assurance Advisory Committee2018
 COM-002005National Mammography Quality Assurance Advisory Committee2017
 COM-002253National Mammography Quality Assurance Advisory Committee2016
 COM-003760National Mammography Quality Assurance Advisory Committee2015
 COM-004364National Mammography Quality Assurance Advisory Committee2014
 COM-006232National Mammography Quality Assurance Advisory Committee2013
 COM-006911National Mammography Quality Assurance Advisory Committee2012
 COM-008338National Mammography Quality Assurance Advisory Committee2011
 COM-009009National Mammography Quality Assurance Advisory Committee2010
 COM-010063National Mammography Quality Assurance Advisory Committee2009
 COM-010951National Mammography Quality Assurance Advisory Committee2008
 COM-012201National Mammography Quality Assurance Advisory Committee2007
 COM-012546National Mammography Quality Assurance Advisory Committee2006
 COM-013925National Mammography Quality Assurance Advisory Committee2005
 COM-014683National Mammography Quality Assurance Advisory Committee2004
 COM-016008National Mammography Quality Assurance Advisory Committee2003
 COM-016723National Mammography Quality Assurance Advisory Committee2002
 COM-017616National Mammography Quality Assurance Advisory Committee2001
 COM-018411National Mammography Quality Assurance Advisory Committee2000
 COM-019573National Mammography Quality Assurance Advisory Committee1999
 COM-020567National Mammography Quality Assurance Advisory Committee1998
 COM-021603National Mammography Quality Assurance Advisory Committee1997